This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more. https://hubs.ly/Q0395bMw0
This edition covers the implications of a jump in Medicare Part D spending on diabetes drugs, news that Madrigal Pharmaceuticals’ launch is going “exceptionally well” and much more. https://hubs.ly/Q0395bMw0